Researchers at LSTM and Imperial College London have designed drugs which could help combat any potential new flu pandemic, by targeting the receptors of the cells by which the virus gains entry to the human body.
In a paper published today(link is external) in the Journal of Immunology the team, led by LSTM’s Professor Richard Pleass, show that by engineering a part of an antibody they can target the viral proteins that allow flu to mutate and become so deadly to humans.
Last year marked the centenary of the 1918 influenza pandemic that claimed nearly 100 million lives worldwide, thus becoming the deadliest disease outbreak in recorded history. Global annual influenza outbreaks account for 300,000-650,000 respiratory deaths, mostly in children and the elderly.
Professor Pleass explained: “Influenza vaccines have limited public health impact during pandemics, and current influenza vaccines are less efficacious than vaccines for many other infectious diseases. This is because influenza viruses that circulate in human and animal populations mutate two key viral surface proteins, haemagglutinin (HA) and neuraminidase (NA), thus allowing them to escape from protective antibodies produced through natural infection or vaccination”
Both HA and NA target a sugar called sialic acid, that is found in abundance on the receptors of cells lining the mammalian respiratory tract, which the virus uses to gain entry into the body. The sialic acid-binding contacts on HA and NA do not mutate readily, otherwise the virus would not be able to infect human cells.
The team has engineered antibody Fc fragments with enhanced sialic acid that target these conserved parts of both HA and NA, binding influenza viruses and thus blocking their interactions with human cells.
By targeting sialic acid, these engineered biologicals may also be useful in the control of other pathogens, such as group B streptococci, Streptococcus pneumoniae, Mycoplasma genitalium, and Newcastle Disease Virus.
“Better anti-influenza therapeutics are urgently needed.” Continued Professor Pleass: “The transfer of antibodies from people recovering from influenza during the 1918 and 2009 pandemics reduced mortality from influenza by 50% and 26% respectively. However, to be useful, these antibody medicines (also called FLU-IVIG) need to be manufactured in advance of future epidemics, which is obviously problematic as there may be modest or little neutralising activity against newly emerging strains. Therefore, combinations of existing medicines, including FLU-IVIG, with sialic acid blockers could increase their efficacy while future-proofing against the next pandemic.”
Professor Sara Marshall, Head of Clinical and Physiological Sciences at the Wellcome Trust, who provided funding for this work, said: “This is a fascinating project, and one which could have really far-reaching impact not only for influenza but as a platform technology to develop new medicines for many other diseases that are currently treated by antibodies.”
The technology described is available for licensing.
The Latest on: Anti-influenza drugs
[google_news title=”” keyword=”anti-influenza drugs” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Anti-influenza drugs
- What doctors wish patients knew about flu vaccines | Commentaryon September 27, 2023 at 8:44 am
Yet, only 49% planned to get an influenza vaccine during the 2022–2023 flu season. That percentage is likely to be even lower this year, given COVID fatigue and the barrage of anti-vaccine propaganda ...
- NH urges schools, parents to take flu, COVID season seriouslyon September 27, 2023 at 2:13 am
New Hampshire officials are urging parents to be mindful of respiratory illnesses in 2023-24. Here's what to know.
- How antiviral drugs could be the next weapon against coronaviruson September 21, 2023 at 12:07 am
One reason is that the development of these drugs has often been bumpy — or worse. One dramatic example: When an explosion in the Arizona desert blew the top off of a reactant vessel, it held up the ...
- H5N1 Influenza — Continuing Evolution and Spreadon September 20, 2023 at 5:00 pm
Another key question is whether these clades and subclades vary in sensitivity to available anti-influenza drugs. The majority of H5N1 clade 1 viruses (e.g., A/Vietnam/1203/2004) are resistant to ...
- Some popular cold, flu drugs may be ineffectiveon September 18, 2023 at 6:31 pm
WHAT DRUGS OR WHAT MEDICINE OVER THE COUNTER SHOULD WE BE KIND OF STAYING AWAY FROM WHEN IT COMES DOWN TO COLD AND FLU SEASON? WELL, IN PARTICULAR, THE MEDICINE THAT THE FDA AND THE CDC PUT OUT AS ...
- Repurposed drugs a possible COVID-19 cure? Experts not sureon September 18, 2023 at 5:00 pm
Among the drugs drawing most attention in Japan are Avigan, an anti-flu medicine manufactured by Fujifilm Toyama Chemical Co., and Orbesco, a drug to treat asthma produced by Teijin Pharm Ltd ...
- Limits eased on flu drugon September 17, 2023 at 1:37 am
A controversial anti-flu drug is to be made more easily available to vulnerable patients if an epidemic breaks out. Brighton and Hove Primary Care Group is to train chemists based in the city so ...
- Management of Influenza: Use of New Antivirals and Resistance in Perspectiveon September 10, 2023 at 5:00 pm
Neuraminidase inhibitors (NAIs) are potent and selective drugs that inhibit influenza ... In contrast to the M2 inhibitors, NAIs have broader anti-influenza activity, better tolerance than ...
- Anti-influenza Drugs Market Share Report 2023-2030 | 86 Pages Reporton September 10, 2023 at 4:27 am
Short Description About Anti-influenza Drugs Market: The Global Anti-influenza Drugs market is anticipated to rise at a considerable rate during the forecast period, between 2023 and 2030.
- Influenza (Flu) Antiviral Drugs Market Size Report 2023-2030 | 115 Pages Reporton September 10, 2023 at 4:25 am
Short Description About Influenza (Flu) Antiviral Drugs Market: The Global Influenza (Flu) Antiviral Drugs market is anticipated to rise at a considerable rate during the forecast period ...
via Bing News